Patents by Inventor Robert M. Raleigh, Jr.

Robert M. Raleigh, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7291324
    Abstract: Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution cleanses the bowels and colon in preparation for diagnostic colonoscopy, without the profuse uncontrollable diarrhea that typically follows either ingestion of large volume isotonic ravages, or smaller volume hypertonic lavages.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: November 6, 2007
    Assignee: Braintree Laboratories Inc.
    Inventors: Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Mark V B. Cleveland, Russell W. Pelham
  • Patent number: 6875445
    Abstract: A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: April 5, 2005
    Assignee: Nabi Biopharmaceuticals
    Inventors: Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Bruce H. Aronson
  • Patent number: 6576665
    Abstract: A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: June 10, 2003
    Assignee: Braintree Laboratories, Inc.
    Inventors: Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Bruce H. Aronson